Financial Ratios

BACIL PHARMA LTD.

NSE : NABSE : 524516ISIN CODE : INE711D01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE20.280.39 (+1.96 %)
PREV CLOSE ( ) 19.89
OPEN PRICE ( ) 20.28
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2500
TODAY'S LOW / HIGH ( )20.28 20.28
52 WK LOW / HIGH ( ) 4.6819.89
NSE
This Company is not listed in NSE
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-0.17-6.55-0.41-0.54-0.58
   CEPS(Rs)-0.17-6.55-0.40-0.52-0.57
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)0.781.001.281.272.16
   Tax Rate(%)0.040.010.180.130.32
Margin Ratios
   Core EBITDA Margin(%)
   EBIT Margin(%)
   Pre Tax Margin(%)
   PAT Margin (%)
   Cash Profit Margin (%)
Performance Ratios
   ROA(%)-9.37-150.07-6.06-7.56-7.53
   ROE(%)-19.41-575.48-31.82-31.16-23.83
   ROCE(%)-8.44-273.27-15.05-17.20-16.18
   Asset Turnover(x)0.000.000.000.000.00
   Sales/Fixed Asset(x)0.000.000.000.000.00
   Working Capital/Sales(x)0.000.000.000.000.00
Efficiency Ratios
   Fixed Capital/Sales(x)
   Receivable days
   Inventory Days
   Payable days
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-32.55-0.88-7.84-3.170.00
   Price/Book(x)6.985.752.441.300.00
   Yield(%)0.000.000.000.00
   EV/Net Sales(x)
   EV/Core EBITDA(x)-32.95-0.82-8.32-3.69-17.64
   EV/EBIT(x)-32.07-0.82-8.15-3.59-17.18
   EV/CE(x)3.192.730.480.281.33
   M Cap / Sales
Growth Ratio
   Net Sales Growth(%)
   Core EBITDA Growth(%)97.47-1575.7922.7910.82-1474.15
   EBIT Growth(%)97.40-1542.2123.2510.7990.79
   PAT Growth(%)97.36-1513.4124.107.9290.87
   EPS Growth(%)97.36-1513.4324.107.9290.87
Financial Stability Ratios
   Total Debt/Equity(x)0.020.030.130.120.05
   Current Ratio(x)8.196.690.110.110.21
   Quick Ratio(x)8.196.690.110.110.21
   Interest Cover(x)-66.68-4517.88-50.34-32.51-1476.86
   Total Debt/Mcap(x)0.010.010.100.17

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.